Research programme: diabetes therapy - NPS Pharmaceuticals

Drug Profile

Research programme: diabetes therapy - NPS Pharmaceuticals

Alternative Names: diabetes therapy research programme - NPS Pharmaceuticals; R 467

Latest Information Update: 14 May 2007

Price : $50

At a glance

  • Originator NPS Pharmaceuticals
  • Class
  • Mechanism of Action Calcium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 29 Jul 2003 Preclinical trials in Diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top